CTOs on the Move

Kala Pharmaceuticals

www.kalarx.com

 
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kalarx.com
  • 100 Beaver St. Suite 201
    Waltham, MA USA 02453
  • Phone: 781.996.5252

Executives

Name Title Contact Details

Funding

Kala Pharmaceuticals raised $68M on 04/13/2016
Kala Pharmaceuticals raised $125M on 05/12/2021

Similar Companies

Acreage Holdings

Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company`s national retail store ‎brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ‎seamless, consumer-focused, branded experience.

Elevation Pharmaceuticals

Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease.

Asymchem Laboratories

Asymchem Laboratories is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strategyx

Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.